Salmeterol/fluticasone propionate (50/250 μg) combination is superior to double dose fluticasone (500 μg) for the treatment of symptomatic moderate asthma

被引:0
|
作者
Bergmann, KC
Lindemann, L
Braun, R
Steinkamp, G
机构
[1] Allergie & Asthmaklin, D-33175 Bad Lippspringe, Germany
[2] Clin Res, Hannover, Germany
关键词
asthma; fluticasone; salmeterol; inhaled corticosteroids; lung function; quality of life; treatment;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Questions under study: if patients with asthma remain symptomatic in spite of chronic treatment with inhaled corticosteroids (ICS), increasing the ICS dosage or adding another drug to the treatment regimen are possible therapeutic alternatives. We compared the efficacy and safety of combined salmeterol fluticasone therapy (SFC, 501250 mug twice daily) with twice the dose of fluticasone propionate (FP, 500 mug b.i.d.) in symptomatic asthmatics. Methods: this prospective, double-blind study was conducted in 76 study centres. 365 symptomatic patients with moderate asthma aged >18 years and receiving ICS in a dose equivalent to 1,000 mug beclomethasone propionate per day were randomly assigned to receive either salmeterol xinafoate (50 mug) and fluticasone propionate (250 mug) in a single dry powder inhaler (Diskus(R)) or 500 mug FP twice daily. The primary efficacy endpoint was morning peak expiratory flow rate (PEFR). Secondary measurements included forced expiratory volume in 1 second (FEV1), asthma symptom scores, and use of rescue medication. Results: combined salmeterol fluticasone therapy resulted in significantly greater improvements in PEFR and symptom control than doubling the dose of FP. At week 12, morning PEFR had increased by 52 L/min from baseline in patients on SFC and by 36 L/min in subjects receiving FR The adjusted difference between groups was 16.6 L/min (95% confidence interval, 1.1 to 32.0 L/min). In the SFC group, the percentage of symptom-free days increased from baseline by 49% of days as compared with 38% of days after FP (adjusted difference: 12.6% of days, 95 % Cl 4.0 to 20.7). Quality of life improved to a greater degree after SFC therapy, and patients regarded study drugs as superior to their previous asthma medication. Adverse event profiles were similar between groups. Conclusions: the combination of salmeterol 50 mug and fluticasone 250 mug in a single dry powder inhaler was superior to twice the dose of FP (500 mug). It seems justified to add salmeterol rather than increasing the ICS dose if symptomatic asthmatics require supplementary therapy.
引用
收藏
页码:50 / 58
页数:13
相关论文
共 50 条
  • [21] Salmeterol/fluticasone propionate vs. double dose fluticasone propionate on lung function and asthma control in children
    de Blic, Jacques
    Ogorodova, Ludmila
    Klink, Rabih
    Sidorenko, Irina
    Valiulis, Arunas
    Hofman, Jerzy
    Bennedbaek, Olav
    Anderton, Sally
    Attali, Valerie
    Desfougeres, Jean-Luc
    Poterre, Marc
    PEDIATRIC ALLERGY AND IMMUNOLOGY, 2009, 20 (08) : 763 - 771
  • [22] Salmeterol/fluticasone propionate (50/100 μg) in combination in a Diskus™ inhaler (Seretide™) is effective and safe in children with asthma
    Van den Berg, NJ
    Ossip, MS
    Hederos, CA
    Anttila, H
    Ribeiro, BL
    Davies, PI
    PEDIATRIC PULMONOLOGY, 2000, 30 (02) : 97 - 105
  • [23] Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 μg twice daily and budesonide 800 μg twice daily in the treatment of adults and adolescents with asthma
    Lundbäck, B
    Jenkins, C
    Price, MJ
    Thwaites, RMA
    RESPIRATORY MEDICINE, 2000, 94 (07) : 724 - 732
  • [24] A comparison of fluticasone propionate 250 μg/day with beclomethasone dipropionate 500 μg/day in adult asthma
    Radulovic, S
    Stankovic, I
    ALLERGY, 2002, 57 : 340 - 340
  • [25] Cost-effectiveness analysis of salmeterol/fluticasone propionate 50/100μg vs fluticasone propionate 100μg in adults and adolescents with asthma III:: Results
    Johansson, G
    Price, MJ
    Sondhi, S
    PHARMACOECONOMICS, 1999, 16 (Suppl 2) : 15 - 21
  • [26] Stepping down to fluticasone propionate or a lower dose of fluticasone propionate/salmeterol combination in asthma patients recently initiating combination therapy
    Hagiwara, May
    Delea, Thomas E.
    Stanford, Richard H.
    Stempel, David A.
    ALLERGY AND ASTHMA PROCEEDINGS, 2010, 31 (03) : 203 - 210
  • [27] Addition of salmeterol to fluticasone propionate treatment in moderate-to-severe asthma
    Ind, PW
    Dal Negro, R
    Colman, NC
    Fletcher, CP
    Browning, D
    James, MH
    RESPIRATORY MEDICINE, 2003, 97 (05) : 555 - 562
  • [28] The salmeterol/fluticasone propionate (50/250mcg) dry powder combination Diskus® has a faster onset of effect compared with salmeterol or fluticasone propionate in patients with asthma.
    Lumry, W
    Windom, H
    Mendelson, L
    Pedinoff, A
    Prillaman, B
    Baitinger, L
    Woodring, A
    House, K
    Shah, T
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1999, 103 (01) : S132 - S132
  • [29] Cost-Effectiveness Analysis of Salmeterol/Fluticasone Propionate 50/100μg vs Fluticasone Propionate 100μg in Adults and Adolescents with Asthma III: Results
    Gunnar Johansson
    Martin J. Price
    Seema Sondhi
    PharmacoEconomics, 1999, 16 : 15 - 21
  • [30] An observational study of fixed dose combination fluticasone propionate/salmeterol or fluticasone propionate alone on asthma-related outcomes
    Stanford, Richard H.
    Fuhlbrigge, Anne
    Riedel, Aylin
    Rey, Gabriel Gomez
    Stempel, David A.
    CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (11) : 3141 - 3148